Zimmer Biomet Holdings, Inc.
ZBH · Price history
Price at last available close
$96.39
+$5.05 (+5.53%) 1M
2026-10-28
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Zimmer Biomet Holdings, Inc.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific.
How they make money
Zimmer Biomet generates revenue by designing, manufacturing, and marketing musculoskeletal medical devices and related technologies. The company sells its products primarily to hospitals, ambulatory surgical centers, and healthcare professionals, utilizing a global sales force that is currently transitioning from independent agents to direct employees to improve commercial performance.
Products & services
The company provides a comprehensive portfolio of orthopedic reconstructive products, including knee and hip implants, as well as S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial, and Thoracic) products, and integrated digital and robotic surgical technologies.
Brands & revenue mix
No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Period ended 2025-12-31Source
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Customer concentration
The company does not disclose any single customer that accounts for 10% or more of its total net sales for the fiscal year ended December 31, 2025.
Suppliers, materials & equipment
- Contract manufacturing and raw material suppliers — The company relies on various third-party suppliers for raw materials, components, and contract manufacturing services to support its global production operations.Source
Competitors
- Stryker Corporation — Competes across various orthopedic and medical technology product categories.Source
- DePuy Synthes (Johnson & Johnson) — Competes in the global orthopedic reconstructive and trauma markets.Source
- Smith & Nephew plc — Competes in orthopedic reconstruction, sports medicine, and trauma markets.Source
Strengths
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
33
Poor
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
50
Fair
Financial Strength
43
Business Quality / Moat
58
Management
54
Growth Quality
38
Risk / Durability
68
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
44
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
50/100
Building Historical Record
Model Score 50/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently moderate.
- •Recent buyback activity is present
- •Valuation is a weaker part of the current profile
- •Revenue fundamentals are weak
- •Debt / balance-sheet profile needs attention
Company-specific research
Questions worth answering for ZBH
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can ZBH maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is ZBH's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •Is ZBH's debt load manageable relative to cash generation, interest costs and upcoming maturities?
- •What future growth or profitability would be needed to justify ZBH's current valuation?
Essential Investment Snapshot
Wall Street Score
33
Opportunity Score
44
Market Cap
$18.39B
P/E Ratio
21.3
EPS
$4.13
52-Week High
$106.88
52-Week Low
$79.12
Beta
0.47
Intrinsic Value
$83.46
Analyst Target
$104.00
Shares Outstanding
198.7M
Total Revenue
$8.51B
Total Debt
$7.48B
Dividend
No current dividend
Liquidation Value / Share
$63.58
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Neutral / mixed momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for ZBH
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on ZBH.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Global leadership in musculoskeletal healthcare with 90+ years of experience.
- +Comprehensive portfolio of integrated digital and robotic technologies.
- +Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Devices industry.
- −Disruptions and challenges associated with the multi-year initiative to convert the U.S. sales force to employees.
- −Intense competition and pricing pressures in the medical device industry.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
2 historical score records availablePrevious Score
32
Jul 24, 2026
Change
+1.1
points
Current Score
33
Oct 1, 2026
Category Changes
ZBH increased 1.1 points because Revenue improved by 2.1 points, Capital improved by 5 points, Valuation improved by 2.4 points.
Positive Contributors
- + Revenue improved by 2.1 points
- + Capital improved by 5 points
- + Valuation improved by 2.4 points
Projected Score
Projected Score
38
Projected Change
+5.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 5.0 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
OvervaluedCurrent Price
$96.39
Model Intrinsic Value
$83.46
Difference
+$12.93
+15.5% vs IV
Margin of Safety
-15.5%
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.51B | $8.23B | $7.68B | $7.39B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | $2.56B | $3.16B | $2.19B | $2.08B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | $5.95B | $5.07B | $5.49B | $5.31B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | $442.9M | $458.5M | $437.4M | $458.7M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | $3.43B | $3.25B | $2.93B | $2.84B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | $4.61B | $3.71B | $4.20B | $4.03B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | $1.96B | $2.22B | $2.25B | $2.22B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | $1.34B | $1.36B | $1.29B | $1.28B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | $289.0M | $292.8M | $218.0M | $201.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | $933.6M | $830.8M | $1.04B | $1.07B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | $126.6M | $125.7M | $131.4M | $42.2M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | $806.8M | $705.2M | $903.8M | $1.02B | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | $4.13 | $3.56 | $4.45 | $4.91 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 192M | 198M | 203M | 209M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 193M | 199M | 204M | 210M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$2.18B
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
$1.03
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
-1.2%
Cash Change
-26.4%
Margin Change
+1.8 pp
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
- Margins expanded
- Debt reduced
What Weakened
- Cash position declined
Potential Score Impact
Positive indicators included revenue growth, EPS growth, debt levels, net income margin. Pressure indicators included cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 4.8%. EPS increased 33.8%. Cash declined 26.4%. Total debt declined 1.2%. Net income margin improved by 1.8 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
32
Smart Money
32
Number of Gurus
3
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
2 historical records2 historical score records available.
Historical Score Chart
2 of 2 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
Medical - DevicesNews
Should Value Investors Buy Zimmer Biomet (ZBH) Stock?
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shareholders to Get $0.24 Quarterly Dividend
Zimmer Biomet Holdings, Inc. $ZBH Holdings Lifted by State Street Corp
Rumor Mill · ZBH
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial